CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S
Advertisement
CMC Biologics A/S announced that it has entered into an agreement with Symphogen A/S for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen's development pipeline. Terms of the agreement were not disclosed.
"We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology," said Mads Laustsen, CEO of CMC.